launch coverag alpha seri descript
outperform rate price think
could best-in-class inhibitor deliv risk-adjust sale follicular
lymphoma fl potenti upsid addit indic fulli account
model discuss expert detail full report think inhibitor
space catch second wind slowli forget gilead zydelig give space
wors name deserv incorpor clever dose regimen limit on-target toxic
total get potenti expand addit combin like second-lin
fl rituximab let look link report top right
predict second wind inhibitor think could lead way
color past mix enthusiasm disappoint think good target
inhibit lead rapid durabl respons certain patient b-cell malign
issu first-to-market product gilead zydelig idelalisib
particularli bad exampl class inhibitor idelalisib activ drug still
sale associ discontinu rate clinic trial box
warn sever severe/fat progress sinc idelalisib approv
inhibitor greater select profil test clever
dose regimen think great exampl next-gener
inhibitor compani attract risk/reward given ev
year left
short interest float
data pleasant surpris import updat come year
report initi efficaci data year report orr
evalu patient non-hodgkin lymphoma cll/sll/fl orr
evalu patient follicular lymphoma fl data got attent market
stock follow day came onto radar chat expert
confer fulli admit small patient number view best early-
stage efficaci data that gener date inhibitor relapsed/refractori r/r
fl patient consist highli select potent drug discuss
next key point think match drug profil clever dose regimen
limit certain on-target toxic win strategi
expect give updat patient might start see thing
like durabl respons incid seriou side effect patient receiv intermitt
dose phase also combin arm patient receiv plu rituximab
new arm start soon beigen bgne btk inhibitor type
b-cell malign repres look forward see rituximab combin
variou patient popul potenti see data patient
data updat phase trial
end begin phase trial support acceler approv r/r fl
result ist avastin patient bc
initi data phase trial voruciclib r/r b-cell malign
analyst certif disclosur pleas see page
alpha seri
lifesci capit alpha seri intend encompass high conviction/impact idea within healthcar sector analys
recommend base deep fundament analysi goal help creat alpha investor long run
close octob
dose next-gen inhibitor good strategi that valid
theme discuss expert dose key improv profil next-
gener inhibitor mantra dose emerg toxic diseas
progress despit fact patient receiv inhibitor achiev respons first
week keep patient drug long durat especi severe/fat advers event
occur mani month therapi median time sever diarrhea/col month perhap dont
need order maintain respons avoid sever expert point data
investig switch patient intermitt dose regimen per week least
week daili exposur result patient discontinu treatment due advers event ae
week induct period patient discontinu treatment due ae continu
dose question whether patient maintain respons durat
plan test trial on-going random fashion safety/efficaci
balanc continu daili dose versu induct daili dose follow intermitt schedul
use weekli intermitt schedul test week week drug
plan explor understand dose regimen would theoret impact regulatori cell
thought main driver side effect like sever diarrhea/col plan initi
random phase trial year end support acceler approv r/r fl patient
opportun follicular lymphoma alon excit first studi support approv acceler
approv r/r fl diseas patient experi long last respons follow
regimen chemotherapi rituximab obinutuzumab patient fail two line therapi
either receiv new inhibitor-bas regimen inhibitor move clinic trial estim
approxim patient us fl use preval median os high
receiv second-lin third-lin treatment respect use think rel
conserv penetr assumpt could gener risk-adjust sale assum me-
take idelalisib market share third-lin could much higher depend profil use
fl patient receiv second-lin therapi
model also assum identifi success commerci anoth
indic achiev fl sale may adjust assumpt compani report addit
phase data patient b-cell malign note like fact steadi flow trial
data report come months/year
intermitt dose could big revenu implic fl import consid intermitt
dose might affect safeti profil inhibitor also potenti revenu stream clinic
trial r/r fl patient typic drug month longer cll remain progress free
month stop drug due tox progress new product led median month rang
better significantli reduc sever toxic patient might stay drug longer fact model revenu
build would dose month could still conserv instead think longer
durat therapi major reason ibrutinib success price per month patient
stay drug year
start ask potenti best-in-class inhibitor worth btk inhibitor
base acquisit ibrutinib revenu one expert spoke think theoret
good target btk downstream b-cell receptor inhibitor
cleaner safeti profil could renew interest
need break immune-oncolog explor oncolog space look interest opportun
recommend find get littl fatigu immune-oncolog io get top two anti-pd-
agent sale last year everyon want piec realiti still
infanc come understand immun system cancer interact even compani
pursu logic combin strategi base scienc mani biolog sometim complic
expect biggest issu io struggl interpret singl arm studi combin
experiment agent checkpoint inhibitor hope everyon realli learn ido disast
explor io trial design esmo dinner detail see
pracinostat call option minim risk develop larg fund via partnership
pharma hdac inhibitor pracinostat partner helsinn group privat swiss pharmaceut group best
known market aloxi palonosetron prevent chemotherapi induc nausea vomit
deal includ up-front plu potenti develop regulatori sales-bas mileston
tier royalti sale helsinn cover cost on-going phase trial elderli patient acut myeloid
leukemia aml unfit intens chemotherapi assign signific valu program model
see call option minim downsid
let forget two clinic program compani two addit clinical-
stage asset expect gener data voruciclib oral inhibitor in-licens
presag bioscienc septemb test patient across phase trial phase
dose rang studi patient b-cell malign mei ind inhibit lead
downregul protein link resist nyse venclexta venetoclax
mean best path voruciclib could combin venetoclax preclin studi support idea
combin voruciclib venetoclax led synergist anti-canc effect aggress subset diffus
larg b-cell lymphoma dlbcl initi clinic data phase studi expect medic meet
plan explor mechan first glanc seem quit interest refin
view get closer clinic data
mitochondri inhibitor target oxid phosphoryl deplet atp lead cancer cell
death compound test investig sponsor trial patient
breast cancer random vegf inhibitor avastin bevacizumab bevacizumab
placebo interim result show patient combin arm greater inhibit measur cell
prolifer assay expect report final data first half
spoke independ expert better understand mei asset decid recommend
stock key point discuss
heme/onc top transplant
specialist lead univers
east coast familiar
data
could best-in-class base initi orr
data present need time see
safeti profil develop
next-gen inhibitor need better safeti
profil idelalisib much lower discontinu rate
better safeti profil could push earlier
earlier line therapi
professor medicin
head earli phase clinic
trial program cancer center
southwest
opportun safeti profil compat
rituximab
think agent lead overal respons rate
high produc complet remiss
two link
profil
head lymphoma group
univers western europ
activ nhl clinic
trial know
think intermitt dose good
strategi maintain efficaci potenti reduc later-
ultim think earli know better
pay attent durat respons
futur trial updat
associ professor
medicin lead univers
hospit east coast
reason shouldnt good btk sinc
downstream b-cell receptor
physician actual sure would win back
btk inhibitor near market
could get inhibitor cleaner side effect
profil could come aliv
top nhl expert
associ professor lead
institut southwest
think less coliti tg umbralisib
incyt
improv safeti profil could due
intermitt dose
inhibitor clearli lower rate coliti
diarrhea drive preferenti select drug
professor top institut
uk expert
strateg dose regimen could help reduc on-
target side effect circumstanti evid
patient dose gilead discontinu trial
well came drug
evid deplet regulatori cell drive
mani side effect idelalisib although could
cell involv macrophag
one medicin chemist
creat
goal medicin chemistri program take non-
select inhibitor hous ip
protect make select delta isoform
still rememb potent molecul addit
caution need work highli potent anti-
cancer drug lab
posit comment distribut data
goal chemistri program
twelve-month price target base dcf valuat model assum wacc
termin growth rate million fulli dilut share assumpt follow
enter follicular lymphoma market late calendar year mid-fisc year base
trial acceler approv line copanlisib duvelisib follow year file nda
receiv approv could faster prioriti review grant duvelisib reach risk adjust sale
price launch per week averag week treatment across month
assum peak penetr across second third-lin fl total sale come outsid
us model probabl success fl revenu us po fl revenu outsid
us assum identifi success commerci second indic
achiev sale expect fl
pracinostat risk-adjust basi model sale reach base royalti rate
probabl success
approv r/r fl
abl strike
unabl
launch late
activ combin
rituximab second-lin later
sale fl
develop anoth
indic bring
revenu fl
efficacy/safeti balanc
sever
cancer success
launch indic
phase aml could
bring yearli royalti
start
clinic data
pracinostat success
safeti profil me-
intermitt dose
take
market share next-
rituximab
insuffici
market penetr fl
lower predict
pushback payer
face gener
risk thesi
clinic produc encourag phase clinic data develop drug
valid target nonetheless clinic profil registration-direct trial may insuffici support
regulatori think could achiev market approv regulatori
risk remain compani may receiv approv despit signific time financi
market despit posit view market may develop expect sale me-
may ultim meet project
financ compani like financ need conduct trial support acceler
approv guarante compani would abl obtain suffici capit
fund plan develop program commerci activ
intellectu properti ip protect decemb includ patent
term extens compani may fail activ defend ip right obtain expect patent term
tabl content
risk thesi
phase pk studi healthi volunt
phase r/r cll/sll/fl
random phase support acceler approv r/r fl
put data context
market opportun
follicular lymphoma
market opportun pracinostat
pracinostat aml
voruciclib
biotechnolog compani develop treatment cancer pipelin clinic stage asset
figur potenti best-in-class inhibitor expect enter studi year support
acceler approv third-lin follicular lymphoma pracinostat hdac inhibitor test pivot
trial aml patient pracinostat partner helsinn privat swiss pharmaceut group best known
oncolog world market aloxi palonosetron prevent chemotherapi induc nausea
vomit partnership provid near-term upfront elig receiv
potenti develop regulatori sales-bas mileston importantli helsinn pay
develop cost pracinostat mei resourc focus
excit remain asset includ inhibitor voruciclib mitochondri inhibitor
clinic phase develop could see initi clinic data program
figur pipelin clinic stage asset
potent select oral avail inhibitor well valid target b-cell malign
critic intracellular signal molecul downstream receptor rtk gpcr class
contain regulatori catalyt subunit delta gamma subunit
primarili express hematopoiet cell two ubiquit express b-cell
malign inhibitor approv gilead zydelig idelalisib bayer aliqopa copanlisib
verastem copiktra duvelisib delta import inhibit block signal downstream b-
cell receptor copanlisib duvelisib also inhibit alpha gamma respect although clear
discuss expert look agent clinic data advantag fact alpha
inhibit copanlisib lead advers event hyperglycemia otherwis seen
potenc select approv inhibitor candid advanc clinic develop
potent delta isoform cellular valu low nanomolar rang figur newer
agent much greater select delta shown fold increas select alpha beta gamma
rel delta check box regard potenc select one potent
inhibitor develop spoke one medicin chemist work program
year ago still rememb potent molecul work lab highli potent anti-canc drug
requir extra precaut said goal time take core scaffold pathway
therapeut time ip make select delta happi achiev minim
gamma bind although shown also quit select regard kinas kinomescan
clean confirm discuss chemist
figur select catalyt subunit potenc delta isoform
ofarrel et al preclin character novel select potent phosphatidylinositol
delta delta inhibitor ex-vivo activ hematolog malign blood
liu et al highli select intraven inhibitor potent activ tumor
cell line xenograft model molecular cancer therapi
scott et al discoveri sar novel inhibitor identif
winkler et al inhibit abrog immun respons suppress activ
autoimmun inflammatori diseas model chemistri biolog
flinn et al dynamo phase studi duvelisib patient refractori indol non-hodgkin lymphoma
shin et al novel inhibitor synerg pim protein kinas inhibit caus tumor
regress model dlbcl abstract
featur influenc safety/efficaci profil excit initi clinic data present
believ promis evid activ molecul without major liabil also
think big part potenti success stori driven mei sophist around dose nonetheless
would satisfi could point advantag featur molecul
potenc select could explain clinic profil know
differ structur class rest inhibitor much differenti
unless someth specif commonli use core limit efficaci contribut
toxic still note someth uniqu
high volum distribut
therefor readili leav plasma enter
cell figur right show ratio
drug blood versu plasma idelalisib
potenc high
penetr cell consist
pharma use quit low dose mg
daili achiev therapeut level
drug patient
clinic program shown bullet point
complet phase pk studi healthi volunt
relapsed/refractori r/r chronic
dose escal monotherapi r/r cll/sll/fl updat
cohort expans mg monotherapi r/r cll/sll/fl updat
rituximab second-lin cll/sll/fl/dlbcl/mzl updat
zanubrutinib beigen btk inhibitor patient b-cell malign
plan random phase trial r/r fl support acceler approv test intermitt dose
initi expect late
phase pk studi healthi volunt
let dive pk studi briefli set tone discuss around dose optim link
singl dose mg dose depend increas plasma level observ
half-lif hr amend daili dose cro use wide accept assay base
inhibit activ basophil determin plasma figur left show
plasma concentr rel inhibit basophil activ estim
nm ng/ml figur right show simul conduct predict plasma level singl
dose mg see dose mg achiev trough plasma level
import well discuss data consist observ phase
figur plasma
figur simul plasma level rel
dose
trial nhl patient dose daili mg patient trough plasma
level exceed also differ efficaci safeti dose cohort suggest
dose higher mg unnecessari contrari plan explor reduc dose
regimen studi support acceler approv give month induct therapi mg follow
intermitt dose week week drug per cycl trial lead identif
minim biolog effect dose manag seem confid intermitt dose strategi good
compromis also ensur patient plasma drug level level
phase r/r cll/sll/fl
conduct phase open-label dose escal trial evalu monotherapi patient r/r
cll sll fl link studi first detail
result report confer found speak expert data
posit surpris also reflect stock price jump day follow link
poster password admit small dataset
patient orr fl intrigu least especi consid
inhibitor perform equal small studi discuss later cours safety/efficaci
balanc make drug best-in-class safeti profil also look interest right simpli
earli patient treat full understand monitor discontinu
rate grade diarrhea/col result announc end day think orr even
r/r fl pair safeti profil better idelalisib shouldnt hard would well
receiv physician patient
studi design baselin characterist patient enrol r/r cll/sll/fl fail least prior
system therapi prior inhibitor exposur start dose mg base pk result
discuss two addit cohort patient mg mg enrol dose escal
phase goal studi identifi recommend phase dose identifi
mg determin expans cohort began enrol
mg fl cll/sll patient
combin
patient b-cell malign
start januari patient began intermitt dose week week per cycl first receiv
cycl daili also sinc enter collabor test beigen
zanubrutinib btk inhibitor third cohort combin begin enrol soon
tabl figur show baselin patient characterist characterist rel standard
trial type piec initi caught eye median number prior therapi
low end compar phase trial inhibitor r/r fl patient report median prior therapi
howev well see discuss efficaci orr significantli differ look
subset patient fail line therapi
year median rang
number prior therapi median rang
subject prior therapi
subject prior alkyl therapi
subject lymph node cm
diseas respons data think efficaci data impress figur orr among
patient fl focu develop cr rate
among patient fl notic differ respons rate dose
group ultim make sens base pk data note similar initi phase pk studi
patient receiv mg trough plasma level drug exceed true
patient cohort support fact mg patient suffici exposur me-
figur respons rate across dose cohort diseas type
go even dose optim well discuss later compani plan
conduct random trial compar mg daili continu schedul versu mg daili cycl
follow intermitt schedul week week per cycl preliminari data show
intermitt schedul may impact respons durat safeti figur show length time
studi patient fl cohort patient cll/sll cohort gray part bar indic
patient receiv daili dose green indic switch intermitt dose note
patient fl cohort maintain respons day switch dose
interest see data matur goal intermitt dose maintain diseas control
minim chanc sever advers event plan phase test robust way hope
get hint strategi give data updat later year
figur mainten respons follow switch intermitt schedul
prematur comment topic like durat respons median patient follow-up month
time say patient experienc respons quickli true
inhibitor case respons achiev first diseas assess end cycl
time poster present respons durat rang month watch
number keep mind idelalisib copanlisib duvelisib led respons durat
mo mo mo respect think dor line approv agent suffici
especi differenti safeti side
also explor compar data show even small patient popul type
respons rate achiev inhibitor combin enthusiasm heard
expert think efficaci data could indic best-in-class inhibitor
safeti safeti biggest unknown recommend simpli earli
know full profil need data patient longer durat treatment fulli understand
discontinu rate incid grade diarrhea/col two aspect safeti profil expert
consid import figur show report far common ae diarrhea
side effect expect drug class figur patient experienc grade coliti resolv drug
interrupt corticosteroid rememb coliti distinguish diarrhea confirm immun
infiltr done histolog analysi biopsi even ct scan sever diarrhea/colitis/rash
also tend occur month treatment
figur common occur patient treat
realiti diarrhea/col on-target off-diseas side effect potent inhibitor go
level diarrhea/col dose strategi come play continu dose may
work well drug class report patient phase experienc rash given drug
holiday steroid re-develop rash put back onto continu dose schedul
interest see rate recur diarrhea patient initi experienc diarrhea
put intermitt dose durat respons also import understand efficaci
random phase support acceler approv r/r fl
plan initi random phase trial year end support acceler approv
r/r fl compani met fda discuss strategi receiv support explor mg
continu versu intermitt dose design shown figur patient receiv cycl
continu dose mg daili major respons patient treat inhibitor occur
rapidli mei phase respons observ first diseas assess week suggest
week induct therapi suffici patient achiev respons induct patient
random remain continu dose toxic diseas progress pt intermitt dose
pt week week per cycl toxic diseas progress think great trial
design test random fashion intermitt dose impact safeti efficaci also think
even sophist around dose studi investig make adjust
continu intermitt upon emerg lower grade toxic intermitt continu upon
sign relaps ultim person dose modif teas best safety/efficaci balanc me-
figur phase trial design support acceler approv r/r fl
eventu need run random trial support full approv understand would
earlier line therapi combin antibodi base assumpt model sale
second-lin fl
intermitt dose alreadi valid present clinic data trial last
year confer trial test inhibitor patient r/r b-cell malign
link present password
classic phase dose escal trial except studi switch exist patient
intermitt dose schedul long receiv least week continu dose addit new
patient start studi novemb onward receiv mg continu week follow
weekli dose toxic diseas progress similar plan trial except
use intermitt schedul week drug week drug induct time differ
week thing note data
patient discontinu due ae within first week
respons occur first diseas assess week
patient discontinu treatment due ae first week studi
patient discontinu treatment due ae intermitt dose
last two bullet point realli hammer home idea induct period follow intermitt
dose good chanc minim sever side effect least sever enough caus patient
discontinu treatment dont know whether respons maintain weekli drug
preliminari data present respons durat follow switch continu dose unfortun
quantit similar trial patient receiv continu dose
first week make data harder interpret term respons durat
got intermitt schedul right one big question us intermitt schedul right one
use week week drug test weekli believ week
drug could suffici durat regulatori cell replenish clear convers
expert treg thought main caus toxic like sever coliti didnt specif
answer reach detail although point pk model suggest weekli
dose achiev level hour perhap enough exposur weekli basi keep
lymphoma cell bay allow treg recoveri mani subtyp treg differ compart
consid think autoimmun coliti well dive time come back
sophist view
put data context
intrigu data mani reason includ reaction lymphoma expert also
interest see data align result prior studi inhibitor earlier phase
similarli small patient cohort larger phase support acceler approv tabl figur
show data rel phase trial result idelalisib copanlisib umbralisib
much acknowledg earli natur data orr evalu fl patient realli stand
us ignor copanlisib data realli small evalu also know larger approv
trial copanlisib show orr said molecul look potent select
show impress orr umbralisib led orr patient trial suggest activ par
approv agent
figur top-line result compar phase trial inhibitor
evalu
mg
daili
infus day
mg daili
switch mg
weekli
treat
mg
daili
includ analysi
median number
prior
line
includ patient cll/sll
includ addit patient nhl subtyp
includ patient dlbcl
tabl figur show data rel phase trial result idelalisib copanlisib
duvelisib inhibitor approv line fl expect orr come
patient treat think orr patient good place start mention think
orr even r/r fl pair safeti profil better idelalisib would home
figur result phase phase trial inhibitor r/r fl
mg
median number prior
line
mg iv infus day
median durat
follow month
median time therapi
benson et al final result phase studi idelalisib select inhibitor patient relaps
refractori indol non-hodgkin lymphoma inhl journal clinic oncolog
patnaik et al first-in-human phase studi copanlisib intraven pan-class
phosphatidylinositol inhibitor patient advanc solid tumor non-hodgkin lymphoma annal
forero-torr et al result phase studi potent highli select inhibitor
patient relaps refractori b-cell malign oral present
burri et al umbralisib novel casein inhibitor relaps refractori chronic
lymphocyt leukaemia lymphoma open-label phase dose-escal first-in-human studi lancet oncolog
discontinu due ae
rate inhl studi
diarrhea grade
includ patient cll/sll
approv drug suffici inhibitor space unfairli repres idelalisib
great drug discontinu rate high associ severe/fat hepatotox
diarrhea/col pneumon infect intestin perfor make thing wors gilead stop studi
spring higher rate death observ trial patient earlier line therapi
dampen enthusiasm physician commun see script number ramp quit well
settl prescript per month us accord symphoni health data let
get confus good target r/r fl patient put least half respons
coupl cycl experienc deep last respons hear expert physician realli
want safer drug product better discontinu rate prefer hear other physician
want drug high chanc induc respons either case neither newli approv agent provid
copanlisib efficaci discontinu rate isnt bad talk iv drug oral
anoth set safeti issu obviou hyperglycemia hypertens duvelisib mediocr respons
rate fl orr discontinu rate slightli improv approv studi fl versu
idelalisib inhl
real competit realli make sens ev term inhibitor
develop think tg actual good molecul relev
competitor also test intermitt dose regimen compar continu dose discuss
elect week continu dose follow weekli also broad clinic program
span major nhl subtyp fl dlbcl margin zone lymphoma mantl cell lymphoma well
myelofibrosi combin studi rituximab ibrutinib combin studi obinutuzumab
bendamustin end day realiz difficult compet larger player space
think enterpris valu under-valued
regard mechan like fortyseven data antibodi rituximab report
orr cr cohort r/r fl patient plan watch data matur small
sall et al efficaci safeti idelalisib patient relaps rituximab- alkyl agent-refractori
follicular lymphoma subgroup analysi phase studi haematologica
dreyl et al copanlisib patient relaps refractori follicular lymphoma journal clinic oncolog
present eha confer phase studi demonstr clinic activ safeti duvelisib patient
double-refractori follicular lymphoma
patient cohort also remind everyon orr nivolumab evalu r/r fl patient
phase studi came patient evalu mei data
also small patient popul patient singl agent rituximab could drive
activ via valid mechan
market opportun
follicular lymphoma
assum follow revenu build treatment follicular lymphoma
preval use preval estim incid number due long overal
surviv fl median os creat larg pool patient need treatment
use two method determin preval chose midpoint two valu first
method appli preval rate base uk demograph studi
patient us second method use preval nhl seer databas
estim percentag fl
growth rate fl understand fl incid larg stabl appli growth rate
equal increas total us popul per year
patient receiv treatment fl slow grow cancer alway requir treatment
upon diagnosi cours patient life lymphoma commun refer watch
wait decis abstain treatment base mani factor includ size number
node affect age patient symptom profil one paper estim watch wait percentag
chose percentag patient receiv treatment datamonitor survey us
heme/onc report patient receiv anti-canc therapi
percentag patient receiv second third-lin therapi two estim
percentag patient treat second- third-lin set first estim come
datamonitor survey mention physician report fl patient
receiv second-lin therapi mainten therapi receiv third-lin therapi
mainten therapi second estim come intern model deriv fraction patient
line therapi full detail avail upon request essenti model flow patient
diagnosi post third-lin use assumpt percentag patient seek treatment mortal
rate dlbcl transform rate histor median variou treatment line model
estim patient receiv second-lin therapi receiv third-lin decid
use number datamonitor survey revenu build come real world data
simul
tarella et al life expect follicular lymphoma mainli determin respons first line
treatment long-term survey patient blood
smith et al lymphoma incid surviv preval sub-typ analys uk
haematolog malign research network british journal cancer
armitag weisenburg new approach classifi non-hodgkin lymphoma clinic featur
major histolog subtyp non-hodgkin lymphoma classif project journal clinic oncolog
nooka et al examin follicular lymphoma intern prognost index flipi nation
lymphocar studi nlc prospect us patient cohort treat predominantli commun practic annal
penetr assum launch late calendar year mid-fisc year base
trial acceler approv follow year file nda receiv approv could
faster prioriti review grant duvelisib model sale ramp recent approv
antibodi gazyva obinutuzumab roch chose drug next-
gener inhibitor known target approv nhl would next-gener
inhibitor known target approv nhl fl wherea obinutuzumab approv cll fl
pleas let us know thought happi revisit assumpt percentag increas sale
obinutuzumab known first year make small assumpt full year sale
percentag increas penetr use third-lin fl expect
approv first year launch assum increas penetr peak
continu logic second-lin agent combin rituximab reduc
penetr third-lin patient expos inhibitor second-lin level
penetr rate third-lin assumpt physician elect reserv
inhibitor post-second-lin accord datamonitor idelalisib use third-lin fl patient
assum peak penetr second-lin fl base potenti competit tg
inhibitor promis data forti seven inhibitor potenti approv
inhibitor fact physician still use patient
note discuss expert strong desir chemotherapi free regimen
fl patient total peak penetr across line
price per week consid price cours therapi verastem recent approv copiktra
duvelisib monthli wac less wac idelalisib
copanlisib respect histor durat therapi fl clinic trial month mean cours
duvelisib therapi differ price model assum price per
week instead per month allow us model revenu assumpt approv
dose daili week follow week week drug chose weekli price
mean month cours would similar concept drug like
rituximab obinutuzumab manufactur price weekli dose fact obinutuzumab
wac week therapi calcul cost drug base treatment durat
number pivot gadolin studi rituximab-refractori inhl induct
mainten total cost
durat therapi averag durat therapi inhibitor month clinic
trial fl patient model averag durat therapi month
assumpt fewer sever late-onset translat patient drug longer durat
consid durat conserv total cost therapi pricing/dur model
think reason differenti oncolog drug
ex-u sale assum total sale come outsid us line
obinutuzumab idelalisib account delay ex-u approv model
probabl success consid clinic risk low known well valid
target treatment fl gener initi data patient suggest activ
without unexpect toxic po risk associ regulatori approv fda
cheson et al overal surviv benefit patient rituximab-refractori indol non-hodgkin lymphoma
receiv obinutuzumab bendamustin induct obinutuzumab mainten gadolin studi journal
clinic oncolog
may ultim decid need see data lower dose
intermitt schedul po think differenti profil upon commerci
po give averag po us revenu includ separ po ex-u
sale convers european inhibitor lymphoma expert suggest could
difficult get approv multipl follow-on agent ema reason lower regulatori
commerci po ex-u averag po ex-u sale
assumpt led us probabl adjust sale fl
figur revenu build treatment follicular lymphoma
patient receiv treatment
percentag patient receiv second-lin therapi
percentag patient receiv third-lin therapi
patient receiv second-lin therapi
patient receiv third-lin therapi
price per week increas per year
total week drug
compani report lifesci capit estim
focus fl market assess obviou reason compani
gener clinic data plan launch trial support acceler approv also lot
potenti indic explor phase expans cohort
address upsid potenti includ portfolio premium valuat analysi assum
pharma success find anoth indic drive similar amount revenu fl could
cll dlbcl solid tumor combin checkpoint inhibit
pracinostat hdac inhibitor evalu pivot phase registr trial elderli aml patient unfit
intens chemotherapi phase trial high-risk patient myelodysplast syndrom md
prior exposur hypomethyl agent develop commerci agreement
helsinn healthcar privat pracinostat part agreement helsinn cover develop cost
aml trial compani split cost md studi also receiv up-front payment
elig receiv potenti regulatori sales-bas mileston plu royalti net sale
begin mid-teen us tier up-front interest featur
program includ fact bear cost pivot aml trial free call option pracinostat
seem overcom major issu hdac-azacitidin trial past high discontinu rate
durabl respons phase trial elderli aml patient nonetheless
mani fail random trial hdac inhibitor space valproic acid vorinostat us appli
much valu program point may chang mind dig even program
new data emerg assign probabl success aml studi adjust appropri
market opportun pracinostat
pracinostat aml
assum follow revenu build pracinostat treatment aml
preval use incid aml report seer databas
growth rate aml appli growth rate equal increas total us popul per
year acknowledg may increas incid aml due age popul
although account
patient receiv treatment mei phase trial test pracinostat patient unfit intens
chemotherapi made assumpt elderli aml popul roughli repres
patient elderli aml patient year old receiv chemotherapi within first month
therefor assum aml popul unfit intens chemotherapi
penetr assum pracinostat launch late calendar year earli fiscal year
ramp peak year
mileston royalti assum receiv mileston payment upon
success nda accept anoth mileston payment upon achiev first
sale royalti payment ramp launch
price per month assum price similar recent approv vyxeo pharmaceut
per cours therapi
ex-u sale assum sale come ex-u start year post-u launch base
sale breakdown obinutuzumab vyxeo yet launch outsid us
probabl success mention hdac fail random clinic trial
aml inform suggest pracinostat significantli differenti assum
assumpt led us probabl adjust sale pracinostat consid
royalti rate sale royalti rate sale
figur revenu build pracinostat treatment aml
patient receiv treatment
price cours therapi increas per year
royalti helsinn
mileston payment helsinn
total revenu
compani report lifesci capit estim
medeiro et al data analysi treatment pattern outcom among elderli acut myeloid leukemia
patient unit state annal hematolog
voruciclib
two addit clinical-stag asset expect gener data voruciclib oral
inhibitor in-licens presag bioscienc septemb test patient
across phase trial phase dose rang studi patient b-cell malign mei
ind inhibit lead downregul protein link resist nyse
venclexta mean best path voruciclib could combin venetoclax
preclin studi support idea combin voruciclib venetoclax led synergist anti-canc
effect aggress subset diffus larg b-cell lymphoma clinic data phase studi
expect medic meet
mitochondri inhibitor target oxid phosphoryl deplet atp lead cancer cell
death compound test investig sponsor trial patient
breast cancer random vegf inhibitor avastin bevacizumab bevacizumab
placebo interim result show patient combin arm greater inhibit measur cell
prolifer assay expect report final data first half
patent portfolio includ issu us patent issu foreign patent pend us
patent applic pend foreign patent applic figur show expir ip coverag
asset assum addit patent issu
figur patent expir portfolio includ patent term extens
composit matter
tahir et al potenti mechan resist venetoclax strategi circumv bmc cancer
dey et al voruciclib clinic stage oral inhibitor repress sensit high-risk diffus larg b-
cell lymphoma inhibit scientif report
provis benefit inom tax
lifesci capit compani report
chang account payabl
chang unearn revenu
chang net oper asset
net cash provid use oper activ
net cash use invest activ
issuanc common stock
proce exercis stock option net repurchas
net cash provid financ activ
net increas decreas cash equival restrict cash
cash equival begin period
cash equival end period
lifesci capit compani report
lifesci capit compani report
premium platform
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect secur subject
compani research analyst cover research view express report accur reflect person view
subject secur subject compani part research analyst compens directli
indirectli relat specif recommend view express research analyst report
